IL28B

[HopefulforSVR]

Hi everyone, was wondering if anyone knows how one would do on triple therapy with Victrelis with a TC alleles. I just got my result and I am a TC.  I plan on treating with Victrelis in January or February next year.  I am a G1a, the last vl taken back in April was around 450,000.  

[flcyclist]

'From Merck:
IL28B genotype helped predict likelihood of treatment response

In pre-specified analyses of the pivotal Phase III studies, researchers found that IL28B status (CC, CT or TT) was a strong baseline predictor of viral response at treatment week 4, week 8 and SVR among patients receiving VICTRELIS. Among those carrying the CC gene allele, 89 percent of treatment-naïve patients and 82 percent of treatment-failure patients had an early response, defined by undetectable virus (HCV-RNA) at treatment week 8, and were eligible for a shorter duration of therapy. Among those with the less favorable gene allele (CT or TT), 52 percent of treatment-naïve patients and 48 percent of treatment-failure patients had an early response and were eligible for a shorter duration of therapy. The analyses also showed that response after the 4-week lead-in was a stronger predictor of SVR than any single baseline variable, including IL28B status.

http://www.merck.com/newsroom/news-release-archive/research-and-development/2011_0331a.html

[willbb]

This was the tela ad hoc study

The largest improvements in response, however, were observed in patients with the CT and TT alleles – the addition of telaprevir doubled and even tripled SVR rates, Dr. Jacobson said. SVR rates in the CT group reached 71% with 12-week telaprevir plus PR, 57% with 8-week telaprevir plus PR, and 25% with PR alone. SVR rates in the TT group were 73%, 59% and 23%, respectively.

[can-do-man]

In the boceprevir-containing arms of SPRINT-2, 80% to 82% of patient with the CC genotype achieved SVR. Importantly, nearly 90% of patients with the CC genotype were eligible for shorter duration of therapy (28 weeks). Thus, although CC patients may not achieve higher SVR rates with boceprevir combination therapy vs pegIFN/RBV alone for 48 weeks, the advantage is that the majority qualify for shorter therapy (28 weeks). Boceprevir substantially improved SVR rates for patients with the CT and TT genotypes: SVR rates were 71% and 59% for CT and TT genotype patients in the BOC + PR48 arm and 65% and 55% for those in the BOC + PR-RGT arm, respectively. Therefore, adding a protease inhibitor clearly helps boost SVR rates for these patients with difficult-to-treat infections.

[willbb]

I don"t know for certain if there was any ad- hoc studies done in the boceprevir trials according to the different alleles,however there was one done  in the Telapravir trials and there was a significant improvement on success rates for both the CT and TT alleles over and above the success with doing just  Interferon and Riba.    
Good luck with your upcoming treatment.
Will.